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Measles virus infection diminishes preexisting
antibodies that offer protection from
other pathogens
Michael J. Mina1,2,3*†, Tomasz Kula1,2, Yumei Leng1, Mamie Li2, Rory D. de Vries4, Mikael Knip5,6,
Heli Siljander5,6, Marian Rewers7, David F. Choy8, Mark S. Wilson8, H. Benjamin Larman9,
Ashley N. Nelson10‡, Diane E. Griffin10, Rik L. de Swart4, Stephen J. Elledge1,2,11†
Measles virus is directly responsible for more than 100,000 deaths yearly. Epidemiological studies have
associated measles with increased morbidity and mortality for years after infection, but the reasons why
are poorly understood. Measles virus infects immune cells, causing acute immune suppression. To
identify and quantify long-term effects of measles on the immune system, we used VirScan, an assay
that tracks antibodies to thousands of pathogen epitopes in blood. We studied 77 unvaccinated children
before and 2 months after natural measles virus infection. Measles caused elimination of 11 to 73% of
the antibody repertoire across individuals. Recovery of antibodies was detected after natural reexposure
to pathogens. Notably, these immune system effects were not observed in infants vaccinated against
MMR (measles, mumps, and rubella), but were confirmed in measles-infected macaques. The reduction
in humoral immune memory after measles infection generates potential vulnerability to future infections,
underscoring the need for widespread vaccination.
I
n the time before vaccination, nearly every
child experienced measles, which resulted
in millions of deaths. Global measles vac-
cination efforts have led to logarithmic re-
ductions in the incidence of measles virus
(MV) infections andmeasles-relatedmortality.
However,measles remains endemic inmuch of
theworld, affecting >7million people annually
and causing >100,000 deaths (1–3). After dec-
ades of decline, the number of worldwide cases
of measles has increased by nearly 300% since
2018 as a result of reduced vaccination (2).
This increase is likely to be accompanied by
substantialmortality risks (3). The resurgence
of measles underscores the importance of
understanding the full consequences of MV
infection and accurately estimating the value
of measles vaccination (4).
Immunosuppression was first documented
when children with measles showed negative
cutaneous tuberculin reactions after previously
testing positive (5). Subsequent studies have
shown decreased interferon signaling, skewed
cytokine responses, lymphopenia, and sup-
pression of lymphocyte proliferation shortly
after infection (6). The MV receptor CD150/
SLAMF1 (signaling lymphocytic activation
molecule familymember 1) is highly expressed
onmemory T, B, and plasma cells, resulting in
their infection and depletion without an effect
on total immunoglobulin G (IgG) levels (7–12).
Recovery of the functional immune response,
including resolution of lymphopenia, occurs 2
to 4 weeks after viral clearance (6, 10, 13, 14).
However, MV replication in immune cells has
been hypothesized to impair immunememory,
potentially causing “immunological amnesia”
(10, 15, 16).
Most bona fide immune memory cells re-
side in the lymphoid tissues and bone mar-
row (17–20). Peripheral blood mononuclear
cells are often used for evaluating immuno-
logical memory repertoires. However, these
cells are in relative flux owing to recent infec-
tions, which limits their utility for measuring
long-term immune memory. Antibodies are
thought tobetter represent long-lived humoral
memory (18, 20). Most antibodies in the pe-
ripheral blood are produced by bone marrow
long-lived plasma cells (LLPCs) and are im-
pervious to disruptions in peripheral memory
cells (17–22). Changes in pathogen-specific
antibodies measured in the peripheral blood
reflect changes in the long-lived permanent
memory repertoire.
Epidemiological evidence has associatedMV
infections with increases in morbidity and
mortality for as long as 5 years (15, 23) and
suggests that in the pre-vaccine era, MV may
have been associated with up to 50% of all
childhood deaths from infectious diseases,
mostly from non-MV infections (15). This
phenomenon might be explained by immune
amnesia. However, to date, no study has suc-
cessfully resolved whether measles-induced
immune amnesia—a reduction in the diver-
sity of the immune memory repertoire after
measles infections—indeed exists. To address
this issue, we have studied paired blood sam-
ples collected before and after MV infection
using a seroprofiling tool that allows the
detection of thousands of pathogen-specific
antibodies.
Measuring the consequences of measles on
immune memory
During a recent measles outbreak in the
Netherlands, families in communities with
low vaccination rates consented to provide
blood samples. Plasma was collected before
and after laboratory-confirmed MV infec-
tion from 77 unimmunized children with a
mean age of 9 (SD ± 2) years, plus five un-
immunized childrenwho remained uninfected
during the study (24). Of the 77 children, 34
were reported to havemildmeasles and 43 to
have severe measles [detailed in (24)]. The
mean time between sample collections was
10 weeks, and mean time of collection after
MV infection was 7 weeks (table S1).
To measure the diversity and magnitude of
the epitope-specific antibody repertoires in
these children and controls, we used VirScan
(25), a phage-display immunoprecipitation
and sequencing (PhIP-Seq) technology (26)
developed for virome-wide detection of anti-
bodies against viral epitopes. VirScan pri-
marily detects antibodies to short contiguous
epitopes as opposed to conformational epitopes.
The cells producing antibodies to all epitopes
are phenotypically similar, aside from their
antibody product. Thus, changes in the anti-
body repertoire detected by VirScan represent
changes across the spectrum of antibodies, and
these include neutralizing and non-neutralizing
antibodies. For this study, we generated an
expanded VirScan library that encodes the full
proteomes of most known human pathogenic
viruses (~400 species and strains) plus many
bacterial proteins. For each sample, we obtained
a comprehensive measure of the individual’s
antipathogen antibody repertoire diversity
(i.e., the total epitope hits across all path-
ogen peptides). We also derived an anti-
body epitope binding signal (EBS), which is
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a relative measure of antibody titer for each
epitope.
We used VirScan to profile the immune
memory antibody repertoires before (time 1)
and after (time 2)MV infection. Paired samples
were also obtained from four control cohorts
(n = 119 paired specimens; table S1). These
samples were derived from: (i) approximately
age-matched controls sampled at similar inter-
vals (~3months) as themeasles cohorts (control
A; n = 28 paired specimens); (ii) age-matched
controls with samples collected ~1 year apart
(control B; n = 31); (iii) adult controls with
collection intervals similar to the measles-
infected individuals (control C; n = 22); (iv)
young children before and after their first
measles-mumps-rubella (MMR) vaccination
(MMRvaccinated;n=33); and (v) unvaccinated
children from the same community as the
MV cases but who remained seronegative for
MV (MV negative; n = 5). Control cohorts A,
B, and C were individuals with no known
exposure to MV.
Measles modulates the diversity of the
antibody repertoire and causes loss of
preexisting antibodies
We assessed changes in antibody repertoire
diversity (measured as the total number of
unique pathogen epitopes recognized, or epi-
tope hits) before and after measles relative to
those observed in controls, standardizing the
total number of epitope hits per individual by
cohort for comparison (Fig. 1A). We detected
substantial reductions in the number of path-
ogen epitopes recognized after measles but
limited changes in the absence of measles.
MV infections were associated with a mean
reduction of ~20% in the overall diversity or
size of the antibody repertoire measured by
VirScan (Fig. 1B), and this was consistent
across individual pathogens (Fig. 1, D and E,
and fig. S1). However, effect sizes varied. No-
tably, 12 of the 77 children (16%) lost >40% of
their overall antibody repertoire diversity. We
detected increases in MV-specific epitopes in
children after measles infection or MMR vac-
cination (Fig. 1C). No changes in the total IgG,
IgA, or IgM levelswere detected, as determined
by quantitative ELISA (enzyme-linked immu-
nosorbent assay) (fig. S2). These results suggest
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Fig. 1. Measles virus infections
reduce antibody diversity.
(A) Total epitopes recognized at
time 1, left, and time 2, right, per
cohort. For comparison across
cohorts, values are standardized
across all samples per cohort to a
mean of 0 and standard deviation of
1. Each gray line indicates a paired
sample from an individual, and black
connecting lines indicate mean
change from zero. Boxplots indicate
interquartile range and median.
Asterisks indicate paired t test
P values. (B) Fold change of total
antibody diversity (i.e., number
of total epitope hits) at time 2 versus
time 1. Each point represents one
paired sample from an individual.
Boxplots indicate interquartile range
and median. Asterisks indicate
significant differences relative to
control A (Cntl A), based on stu-
dent’s t test P values. (C) Number of
measles epitope hits per sample at
time 1 and time 2. Thin lines indicate
paired samples. Black lines indicate
cohort averages. (D) As in (A), but
for individual viruses. Bonferroni-
corrected P values in (A to D): *P <
0.05, **P < 0.001, ***P < 0.001,
****P < 0.0001. (E) Heatmap indi-
cating the change in the total
number of epitope hits per species
between time 1 and time 2. Each
column represents an individual
paired sample and each row a
pathogen. Cohorts are indicated by
the solid bars at top and bottom and
are in the same order (left to right)
as in (A). Yellow cells indicate that
pathogen was not assayed in those
samples. Ab, antibody.
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that, rather than a simple loss of total IgG,
there is a restructuring of the antibody reper-
toire after measles.
To measure the full effect of measles on the
pre-measles repertoire and to circumvent inter-
ference from new exposures during follow-up,
we next restricted analysis to epitopes detected
at the first time point and quantified retention
or loss of epitope recognition. After severe or
mild measles, children lost a median of 40%
(range: 11 to 62%) or 33% (range: 12 to 73%),
respectively, of their total preexisting pathogen-
specific antibody repertoires (Fig. 2A and fig.
S3). In contrast, controls retained ~90%of their
repertoires over similar or longer durations.
Controlling for interval duration in a bino-
mial random effects model (see materials and
methods),we estimated the per-pathogenprob-
ability of antibody retention for each child (Fig.
2, B and C). Loss of antibodies after MV in-
fection varied widely for specific pathogens
and between children. A small fraction of MV-
infected individuals retained antibodies sim-
ilar to the bottom quartile of the controls.
However, the most-affected 20% of children
lost >50% of the pathogen-specific antibodies
for most pathogens. In some of these child-
ren, up to 70% loss was detected for specific
pathogens.
Antibody repertoire retention (~90%) was
similar in control cohorts A and B despite the
longer sampling interval in B compared with
A (1 year versus 3 months). The retained
antibody repertoire could represent a core
stable LLPC repertoire (~90%), and the 10%
that was lost could represent a transient
repertoire derived from IgG-secreting B cells
and plasmablasts. This result is consistent
with previous studies that showed no effect
of immunosuppressive therapy, such as B cell–
depleting anti-CD19 or anti-CD20 treatment,
on retention of the majority of the antibody
repertoire (17, 19, 21, 22). Therefore, measles
is associated with greater loss of antibody-
mediated epitope recognition than can be
explained by ablation of B cells, suggesting a
direct effect on the LLPC compartment.
Measles decreases the strength of
epitope recognition
Simply counting epitope numbers recognized
before and after measles underestimates im-
mune memory impairment because epitope
recognition can be detected even when a large
fraction of cellular clones producing the rele-
vant antibody are eliminated. To quantify the
relative abundance of particular antibodies,
we generated an EBSmetric, which is a z-score
that measures the relative enrichment of an
epitope in a VirScan immunoprecipitation (see
materials and methods). Thus, EBS represents
a VirScan analog of relative antibody titers and
can be measured over time to detect changes
in epitope recognition. Significant increases
in EBS for a given epitope usually indicate a
new exposure during the follow-up interval.
In controls, significant reductions are nor-
mally detected when a recent exposure has
occurred before the first time point, resulting
in a peak around time 1 followed by an ex-
pected rapid decay of the antibody signal that
is detected at time 2.
To evaluate changes in EBS for each path-
ogen species in each child, EBS signals were
clustered by pathogen species and child (EBSPC)
and a paired t test (paired per epitope) was
used to test for significant differences at
time 2 versus time 1. False discovery rate (fdr)–
adjusted P values, sample size, and effect size
(calculated as the fold change of the geomet-
ric mean at time 2 versus time 1) are shown for
each EBSPC cluster (Fig. 3A and fig. S4).
Significant changes in EBSPC were detected
in children in each cohort. Among controls,
these changes were distributed equally, below
and above a fold change of 1, indicating recent
pathogen exposures before time 1 or during
the follow-up interval, respectively. Unlike the
controls, after measles, the significant changes
in pathogen-specific EBSPC were both more
frequent and nearly uniformly negative with
median fold changes (0.58 and 0.62), indicat-
ing ~40% reductions in EBSs (Fig. 3A). The
effect was stronger after severe versus mild
MV infections (P < 0.001). We confirmed these
results by comparing the fold changes in EBSPC
to quantitative ELISA assays for adeno-
virus, enterovirus, and respiratory syncy-
tial virus (RSV) in a selection of children
who had decreased or increased EBS, and
found good correlation (correlation coefficient
r = 0.73; P < 0.001) (fig. S5, A and B).
To further clarify cohort-level changes, we
combined the epitopes from all individuals
and evaluated changes on a per-pathogen-
species basis across each cohort (fig. S6).
Among MV-infected individuals, the median
fold change in EBS measured across all spe-
cies was a strongly negative effect (median
fold change: 0.69 or −31%; P < 0.0001). In
contrast, among controls, the antibody EBS
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Fig. 2. Measles eliminates preexisting immune memory. (A) The proportion
of total epitopes detected at time 1 that were retained at time 2. One point
represents one child. Bonferroni-adjusted student’s t test P values for
significant differences relative to control A are shown (****P < 0.0001).
(B) Probability of retaining initial antibodies at time 2 for individual pathogens
per child. Each point represents a single pathogen per child. Probabilities
are obtained by fitting a binomial random effects model controlling for
interval duration (materials and methods). Each boxplot represents the
interquartile range and median retention probabilities calculated across
pathogens for a single child. Points indicate pathogen-specific retentions
that are outside of the interquartile range per child. Children are rank
ordered along the x axis by the median (black dot per boxplot) retention
probabilities. (C) Density distribution of probabilities shown in (B), derived by
collapsing all points in (B) by cohort. Bonferroni-adjusted Wilcoxon signed
rank test P values for differences relative to control A are shown
(***P < 0.001).
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was significantly changed only for relative-
ly few pathogen species, and these were
roughly balanced between positive and nega-
tive effects.
Measles disrupts recognition of pathogen
epitopes across the cohort
At the cellular level,MVwould not be expected
to preferentially infect particular antibody-
secreting cells on the basis of their pathogen
targets or the type of antibodies produced
(i.e., neutralizing or not). We therefore tested
for cohort-wide differences in EBSs on a per-
epitope basis. Across approximately 1100 epi-
topes each from the control A and B cohorts,
none significantly changed (Fig. 3, B and C,
and fig. S7), indicating that antibody epitope
recognition across a group of individuals is
remarkably stable, even when changes are
detected at the pathogen species level, as in
fig. S6. In contrast, EBS was substantially
reduced in 12% of the 855 epitopes evaluated
aftermildMV infections and in 39%of the 1079
epitopes evaluated after severe MV infec-
tions (P < 0.0001) (Fig. 3, B and C). Only one
epitope in mild measles and three in severe
measles showed a significant increase, <0.2%
overall.
VirScandetects neutralizing antibodieswhen
those antibodies target short contiguous epi-
topes encoded in the phage display. A well-
characterized neutralizing short contiguous
epitope is the 24-amino-acid target of the anti-
RSVmonoclonal antibody therapiespalivizumab
and motavizumab. Among 22 MV-infected
children with antibodies against this neutral-
izing epitope and without evidence of new
RSV exposure, we detected a fold change in
EBS of 0.59 (SD ± 0.18; P < 0.001) (fig. S8), in
line with the observations above and indicat-
ing that the effects ofMV are the same for the
neutralizing and non-neutralizing antibody
repertoires.
The MMR vaccine does not impair the
immune repertoire
Amarked increase in the overall antibody rep-
ertoire diversity was noted in MMR-vaccinated
controls (Fig. 1), indicating that a similar loss
of antibodies does not appear to accompany
receipt of MMR vaccines compared with MV
infections. However, in infants and young chil-
dren, such as the MMR-vaccinated cohort in
this study, the antibody repertoire continues
to add antibody diversity over time (fig. S9).
This is particularly true during the second
year of life, following depletion of maternal
antibodies, when measles vaccines are first
given. These overall increases in antibody di-
versity over time could be obscuring potential
minor impairments from measles vaccine,
especially given the relatively long sampling
interval for the vaccinated controls. To deter-
mine whether viral responses before or after
MMR vaccination might be impaired, we ana-
lyzed EBS for antibodies detected surrounding
MMR vaccine. We found no overall change in
EBS after MMR vaccination (fig. S10), which
is consistent with observations that the MV
vaccine strains are not associated with wide-
spread infection of CD150+ lymphocytes (27, 28).
Thus, this higher-resolution analysis failed to
detect immune impairment at the epitope
level. Combinedwith increased epitope diver-
sity after MMR vaccination (Fig. 1A), this
analysis supports decades of observations
that MMR vaccines do not increase suscep-
tibility to subsequent infections (29, 30).
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Fig. 3. Measles virus infections are associated with diminished epitope binding signal. Epitope binding
signal (EBS) was measured for each epitope. (A) Each point represents one pathogen species per sample
pair. Changes in EBS for all epitopes recognized per pathogen per sample pair were compared using a
Wilcoxon matched-pairs signed rank test. Fdr-adjusted P values (adjusted for a fdr of 5%) are indicated
by color of each symbol. The total number of epitopes included in each paired test (i.e., the number
of epitopes recognized for each species per paired sample) are indicated by the symbol shape. For each
pathogen, the geometric mean (gMean) EBS was calculated at each time and the fold change at time 2
versus time 1 was calculated and indicated by the position of each point along the y axis. Density distributions
adjacent to the points reflect the distribution of points that were significantly changed on the basis of a
fdr P value < 0.05. Only pathogens with antibodies targeting ≥5 epitopes were included. (B) Change in gMean
EBS per epitope, across all paired samples per cohort. Format as in (A), except here each point represents a
single epitope, and the gMean EBS is calculated across all paired samples with the epitope detected. The
color of each point represents the fdr-adjusted Wilcoxon matched-pairs signed rank test P value, and shapes
indicate the number of paired samples per cohort with antibodies against the particular epitope). Only
epitopes recognized in >6 paired samples were included. (C) Scatter plot showing each epitope (point) shown
in (B), but instead of plotting the fold change, the gMean EBS at time 1 (x axis) versus time 2 (y axis) is
plotted. The P values (colors) and samples sizes (shapes) are indicated. MV-specific epitopes were included
and highlighted in green. Epitopes significantly changed in a positive direction are labeled with pathogen
species name. NS, not significant; PIV-4, parainfluenza virus-4.
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Nevertheless, because of the naturally rapidly
increasing antibody diversity in this young
cohort at the time ofMMR receipt, we cannot
definitively rule out the potential for minor
reductions of antibody-producing cells with
measles vaccination.
Reconstruction of the antibody repertoire
with high-transmission pathogens is
spatially clustered
Although antibody diversity and abundance
were negatively affected for almost all path-
ogens, a subset of children had increased EBS
and/or epitope hits for particular pathogens
after measles (Figs. 1, D and E, and 3A; and
figs. S4, S8, and S11), suggestive of potential
restoration of immune memory after the ini-
tial immune depletion.
Across all of the pathogen-child combina-
tions with significantly increased EBS after
measles, 80% were attributable to only six
pathogens: adenovirus C, influenza A virus,
respiratory syncytial virus, human herpesvirus
4 (Epstein-Barr virus; HHV-4), Streptococcus
pneumoniae and Staphylococcus aureus. In
these children, the probability of retaining
preexisting antibodies for these pathogens
was relatively high (fig. S12).
If reconstruction of the antibody repertoire
requires new exposures, children experiencing
repertoire reconstruction for transmissible
pathogens should cluster spatially. Using postal
codes and household identifiers, we observed
clustering of pathogen-specific repertoire re-
construction at both the postal code or school
level and the household level (Fig. 4). Among
19 children with increased adenovirus C anti-
body EBS, eight (42%) came from a single
postal code (number 7) that included only
12 (16%) of the 77measles cases (Fig. 4A). Thus,
children in this postal code had significantly
increased odds [odds ratio (OR) 9.4; Fisher’s
exact test, P < 0.001] of recovering their ade-
novirus C repertoire versus other postal codes,
suggesting recovery is associated with patho-
gen transmission. Moreover, six of these chil-
dren (75%) shared a household with another
child with increased adenovirus C EBS. We
found similar clustering effects for other res-
piratory pathogens: influenza A virus [of eight
children with increased influenza A EBS,
five (63%) were from a single postal code rep-
resenting only 26% of the measles cases (OR
5.8; P < 0.05) and two were from the same
household; Fig. 4B]; RSV [of nine with in-
creased EBS, five (56%) were from the same
postal code (OR4.5;P<0.05) and four of them
(44%) shared a house; Fig. 4C]; rhinovirus [of
12 with increased EBS, eight (67%) shared a
household with at least one other child with
increased rhinovirus EBS]; and S. pneumoniae
[of 13, seven (54%) came from a single postal
code (OR 4.5; P < 0.05) and two shared a
household]. Combined, these indicate local
pathogen transmission and suggest that re-
construction of the antibody repertoire occurs
on a per-pathogen basis and is associated with
new exposures.
In contrast to the highly transmissible respi-
ratory pathogens above, where mean EBS was
increased after measles infection, we found
that for chronic viruses [i.e., HHV-4 and hu-
manherpesvirus 5 (cytomegalovirus; HHV-5)],
there was no evidence of spatial clustering.
Further, only 6 out of 12 individuals (50%)with
increased HHV-4 antibody EBS also devel-
oped antibodies against newHHV-4 epitopes.
HHV-5 behaved similarly, with only 33% of
individuals with increased HHV-5 antibody
EBS also developing new antibodies to pre-
viously untargeted HHV-5 epitopes. The lack
of development of antibodies targeting new
epitopes, despite increases in EBS of existing
antibodies for these two pathogens, is dif-
ferent from what we observed for the more-
transmissible viruses noted above, in which
90% of pathogen-specific increases in EBS at
time 2 were associated with development of
new antibodies against previously unrecog-
nized pathogen-specific epitopes. An increase
in EBS without addition of new epitope rec-
ognition points toward reinfection with or
reactivation of the same virus.
Two additional notable pathogens for which
positive changes in EBS were often detected
after measles were the bacteria S. pneumoniae
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Fig. 4. Increases in antibody epitope binding signal cluster within households
and in postal units. We tested whether individuals with increased EBS indicate
new exposures due to pathogen transmission by looking for evidence of spatial
clustering among children with increases in EBS. In (A to C), each child (node) is
connected by an edge to their postal code (indicated by a central node with an
assigned value, 2 through 7). Children shown as single nodes were the only children
studied from their postal code. Children from the same household are connected by
an edge and encircled by dashed gray ovals. Each of the three viruses where
increases in EBS were most common are shown: (A) adenovirus C, (B) influenza A
virus, and (C) respiratory syncytial virus. Children with significantly increased EBS
for the pathogen (indicating exposure during the interval) are highlighted with red
circles and those with decreased or unchanged EBS with gray circles.
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and S. aureus. Acute viral respiratory infections,
including measles, increase susceptibility to
respiratory bacterial infections (6, 31–33).
After measles, new acquisitions of bacteria
or increased replication of already colonizing
bacteria could elicit antibody responses and
reinstate antibody diversity and protection
against these pathogens. In line with this, we
observed net increases in antibody diversity,
including development of antibodies against
new epitopes, and increases in EBS for S. aureus
[the only pathogen for which a net positive
change in antibody diversity or EBS was de-
tected after measles; 45 of 77 children (58%)
had increased EBS] (Fig. 1 and fig. S11). In-
creases were also observed for S. pneumoniae,
although theoverall cohort-level effect remained
negative.
Reconstruction of the antibody repertoire
through reexposure after measles carries risks
Despite the potential benefits of reinstating
the antibody repertoire, exposure to pathogens
aftermeasles—especially when in the presence
of diminished preexisting immunememory—
can carry risks. Ten of 43 children (23%) with
severemeasleswere diagnosedwith acute otitis
media (AOM;most commonly pneumococcal),
whichwas associatedwith a threefold increase
in odds of carrying greater pneumococcal anti-
body diversity after measles compared with
children without an AOM diagnosis. In addi-
tion, two childrenwithmildmeasles andAOM
and one with a diagnosis of bacterial pneumo-
nia had increased pneumococcal antibody di-
versity at follow-up. Combined, these effects
suggest that the antibody repertoire begins
rebuilding soon after measles, through path-
ogen exposures, and that pathogen exposure
after measles, while serving to reinstate im-
mune memory, may pose excess risk.
Experimental MV infection confirms a
decrease in previously acquired
immune memory
To confirm the findings above using a con-
trolled experimental setting with longer follow-
up, we used VirScan to profile the antibody
repertoire in plasma collected before and
5 months after experimental MV infection of
four rhesus macaques (34). The overall diver-
sity of the antibody repertoire was decreased
an average of 26% (range: 21 to 35%), and
reductions were distributed across pathogens
(Fig. 5A). Notable exceptions were observed
for simian foamy virus and Epstein-Barr virus,
both of which can reactivate during immune
dysregulation and thus may be early con-
tributors to repertoire reconstruction. As
expected, we detected increases in recogni-
tion of MV epitopes (Fig. 5B). Out of 21 MV
epitopes recognized after measles, only one
(phosphoprotein/V protein 29) was recognized
before infection and was reduced by 40%. This
likely represented a cross-reactive epitope that
was diminished along with the rest of the
repertoire.
Eachmonkey lost, on average, 40 to 60% of
its preexisting antibody repertoire (Fig. 5C),
and this loss persisted for at least 5 months
after MV infection. In each monkey, the frac-
tions lost were distributed across the path-
ogens, which is expected for a virus that
indiscriminately infects antibody-secreting
cells.
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Fig. 5. Measles virus infection in
macaques deletes preexisting
immune memory. Four rhesus
macaques (14Y, 31Y, 46Y, and 50Y)
were infected with the Bilthoven
strain of wild-type MV [detailed in
(34)], and plasma samples were
collected before and 5.1 months after
infection. (A) Heatmap showing
the percentage change in total
epitopes recognized per pathogen
in each monkey from time 1 to
time 2. Pathogens with >10 unique
epitopes recognized at either time
point per macaque are shown.
The color and text indicate percent
change in total epitopes recognized
per pathogen species before
versus after infection. (B) Heatmap
showing the signal strength of
anti-measles antibodies (EBS) for
each epitope for which at least
one monkey developed an antibody.
Colors and text of each cell represent
the respective EBS values.Letters
indicate the MV protein (F, fusion
protein; H, hemagglutinin; N, nucleo-
protein; and P, phosphoprotein),
and the numbers indicate the
position along the protein of the first
amino acid of the 56-amino-acid
peptide. (C) The fractions of epitopes
recognized before MV infection
that remained 5 months after are
shown (0 months after infection is
baseline and thus set to 1 for all pathogens). Each gray line indicates a different pathogen, and the dark black line indicates the average across the pathogens. The
boxplot summarizes the interquartile range and median fraction retained across the pathogens.
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Cumulative evidence supports the
establishment of an immune amnesia state
after measles
Using VirScan, we quantified the effects of
measles on antipathogen antibody repertoires
in plasma obtained before and after natural
and experimental MV infections. We found
that measles is associated with large reduc-
tions in both the diversity of the antibody rep-
ertoire and magnitude of the binding signal,
likely reflecting reduced antibody titers result-
ing from diminished numbers of cells produc-
ing the respective antibody. The reduction of
diversity may be greater than we report be-
cause even if particular antibody-producing
cells have been eliminated, an antibody half-
life of ~3 weeks (35) means that residual anti-
bodies were still detectable at the time of
sampling. Our findings show that after recov-
ery from MV infections, individuals enter a
state in which immune functionality is re-
stored, but memory cell elimination induced
by measles may alter previously acquired
memory.
MV can infect 20 to 70% of memory cells,
including B cells, T cells, and plasma cells in
the lymphoid tissue and peripheral blood
during the first 3 to 10 days after infection
(7, 10, 24). Clinical trials of systemic adminis-
tration of engineeredMV for oncolytic therapy
of multiple myeloma also demonstrated effi-
cient entry of MV into the bone marrow and
plasma cell infection (36). In wild-type MV
infections, lymphocytes undergo rapid prolif-
eration during immune activation (37), and
lymphocyte counts (and other immunological
markers) return to normal levels within weeks
of infection. Thus, the immunological toll of
measles is often considered limited to that
period. After experimental MV infection in
monkeys, we found that we could no longer
detect up to 60% of the antibody repertoire,
and this persisted for at least 5 months. This
loss could be permanent, owing to elimina-
tion of B cells as well as LLPCs (11), although
we cannot rule out possible involvement of
additional unknown pleiotropic effects that
may also cause antibody-secreting cells to
down-regulate antibody production. Further-
more, because T cells also express SLAM and
are infected by MV, T cell immunity may be
diminished through similar mechanisms, and
this could explain the loss of cutaneous tu-
berculin reactions after measles (5). Lasting
remissions of autoimmune-related disorders
aftermeasles have beendetected by researchers
since the 1940s (38), supporting the potential
persistence of immune suppression and point-
ing to persistent long-term effects. Because
LLPCs are terminally differentiated and do
not replicate (39), the rebuilding of immune
memory after measles-induced LLPC elimina-
tion would likely require reexposures, either
through natural infection or vaccination; thus
it could potentially take months or years to
return the immune repertoire back to baseline
for all relevant pathogens. During the rebuild-
ing process, individuals would potentially be
at increased risk for other infectious diseases.
Revaccination with routine childhood vac-
cines after measles could help to mitigate
long-term suffering that might stem from
immune amnesia and subsequent increased
susceptibility to other infections.
We previously reported evidence that mea-
sles epidemics link to population mortality 2
to 3 years later (15, 40). We hypothesized that
the observed dynamics could potentially be
explained by an immunomodulatory effect of
measles, similar to what we show here. We
found no such debilitative effects for the live
MMR vaccine (15). Furthermore, because, in
the prevaccine era, MV infected nearly all
children within the first decade of life, the
vaccinemay have contributed to considerably
greater benefits by preventing measles and
immune amnesia. By preserving immunity,
measles vaccines may have reset overall base-
line morbidity and mortality rates to lower
levels (15).
Given the variation in the degree of immune
repertoire modulation we observed, we antic-
ipate that future risk of morbidity and mortal-
ity after measles would not be homogeneous
but would be skewed toward individuals with
the most severe elimination of immunological
memory. These findings underscore the cru-
cial need for continued widespread vaccina-
tion. More than 7million people are estimated
to have been infected with measles in 2018
(1–3). Comprehensive coverage with MV vac-
cine would not only help prevent the >120,000
deaths that will be directly attributed to
measles this year, but, by preventing MV im-
mune amnesia and thus preserving immu-
nity, MV vaccines could also avert potentially
hundreds of thousands of additional deaths
attributable to the lasting damage to the im-
mune system. The WHO recently reported
that between 2000 and 2017,MV vaccines have
preventedmore than 21million deaths directly
attributable to measles (41). These findings
suggest that the number of deaths averted
might be much greater, and they attest to the
immense public health value of the measles
vaccine.
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other pathogens. These adverse effects on the immune system were not seen in vaccinated children.
infection can greatly diminish previously acquired immune memory, potentially leaving individuals at risk for infection by
natural infection with measles virus as well as in children before and after measles vaccination. They found that measles 
 comprehensively analyzed the antibody repertoire in children before and afteret al.a blood test called VirScan, Mina 
unclear. This question has become increasingly important given the resurgence in measles epidemics worldwide. Using
functionally impairs immune cells. Whether measles infection causes long-term damage to immune memory has been 
Many of the deaths attributable to measles virus are caused by secondary infections because the virus infects and
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